# GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

> **NCT00324831** · PHASE3 · SUSPENDED · sponsor: **Favrille** · enrollment: 480 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** autologous immunoglobulin idiotype-KLH conjugate vaccine
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** rituximab
- **DRUG:** sargramostim
- **DRUG:** vincristine
- **PROCEDURE:** Intervention/procedure
- **PROCEDURE:** antibody therapy
- **PROCEDURE:** biological therapy
- **PROCEDURE:** chemotherapy
- **PROCEDURE:** colony-stimulating factor therapy
- **PROCEDURE:** cytokine therapy
- **PROCEDURE:** monoclonal antibody therapy
- **PROCEDURE:** non-specific immune-modulator therapy
- **PROCEDURE:** therapeutic procedure
- **PROCEDURE:** tumor cell derivative vaccine
- **PROCEDURE:** vaccine therapy

## Key facts

- **NCT ID:** NCT00324831
- **Lead sponsor:** Favrille
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324831, "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00324831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*